Search Results

Sylentis Presents New Results on Its Ophthalmological Compounds at ARVO 2018

April 26, 2018

·

2 min read

Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial

Sylentis has reached the target of recruiting patients for its Phase III trial “HELIX” for the treatment of the signs and symptoms of dry eye disease

October 19, 2018

·

8 min read

Drug Development

Sylentis announces results of Phase 3 HELIX trial with tivanisiran for the treatment of Dry Eye Disease

Sylentis, a PharmaMar Group company (MSE:PHM), has announced today the results of the HELIX [i]exploratory clinical trial; a Phase 3 efficacy and safety study with tivanisiran compared against artificial tears for the treatment of dry eye disease

January 31, 2019

·

8 min read

Sylentis Presented New Results for the Treatment of Age Associated Macular Degeneration

Topical administration of siRNA could be a new therapeutic option for the treatment of degenerative illnesses of the retina that presents processes of neovascularization[i].

May 4, 2018

·

3 min read

Drug Development

Sylentis Announces the Clinical Results of Tivanisiran for the Treatment of Dry Eye Syndrome

The studies carried out with tivanisiran showed an improvement in the inflammatory ocular parameters, tear quality, and a reduction in ocular pain, that is associated with dry eye syndrome[i]

May 3, 2018

·

7 min read

Drug Development

Sylentis Initiates A Phase III Study For The Treatment Of Dry Eye Syndrome

June 1, 2017

·

4 min read

PharmaMar: Sylentis Presents New Data On A New Eye Drop siRNA For The Treatment Of Retinal Diseases Avoiding Intraocular Injections

September 26, 2017

·

2 min read